Merck/Moderna cancer vaccine cuts melanoma death or recurrence risk by 42%, shares fall
Summary
A newly developed cancer vaccine from Merck and Moderna successfully lowered the chance of melanoma returning or causing death by nearly half. Despite this significant medical progress, the companies saw their share prices decline following the announcement.
Source: Read the full story at Stock Market News
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.